Rasagiline

• Servier has secured global rights to develop and commercialize BDTX-4933, a Phase 1 targeted therapy designed to address both RAS mutations and RAF alterations in solid tumors, particularly non-small cell lung cancer. • The agreement includes a $70 million upfront payment to Black Diamond Therapeutics, with potential for up to $710 million in additional milestone payments plus tiered royalties on global sales. • BDTX-4933 is currently in Phase 1 trials evaluating safety, dosing, and efficacy in patients with advanced cancers harboring BRAF, CRAF, or NRAS mutations, positioning it as a potential best-in-class treatment for RAF/RAS-mutant solid tumors.

VCU Massey researchers discovered that combining FDA-approved sotorasib with experimental FGTI-2734 effectively overcomes resistance in KRAS G12C-mutated non-small cell lung cancer, potentially offering new hope for the 14% of patients with this mutation.

Phase 1 trial of daraxonrasib (RMC-6236) in RAS-mutant pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging early results.

• Daraxonrasib demonstrates encouraging antitumor activity and manageable safety in RAS-mutated pancreatic ductal adenocarcinoma (PDAC), showing potential to inhibit major RAS variants. • Zoldonrasib, a KRAS G12D-selective inhibitor, exhibits preliminary antitumor activity and is well-tolerated in patients with KRAS G12D-mutated PDAC. • Clinical trials reveal significant reductions in RAS variant allele frequency (VAF) in circulating tumor DNA (ctDNA) with both daraxonrasib and zoldonrasib. • Ongoing phase 3 trial (RASolute 302) will further evaluate daraxonrasib as a second-line treatment for metastatic PDAC compared to chemotherapy.

• Health Canada has approved fruquintinib (Fruzaqla) for adults with metastatic colorectal cancer (mCRC) who have been previously treated with standard therapies. • The approval was based on data from the FRESCO-2 and FRESCO phase 3 trials, which demonstrated improved overall survival compared to placebo. • Fruquintinib is an oral inhibitor of VEGF receptors 1, 2, and 3, working by blocking the formation of new blood vessels in tumors. • This approval provides a new treatment option for Canadian mCRC patients who have limited alternatives, offering hope for slowing disease progression.